Compound Regulatory-Status & Evidence Map
Every compound in the directory, with its regulatory status and the strongest evidence grade it holds for any outcome. Generated directly from our structured content — this table and the downloads are always in sync.
| Compound | Class | Regulatory status | Best evidence (outcome · grade) | WADA |
|---|---|---|---|---|
| BPC-157 | Synthetic pentadecapeptide | Research chemical | Tendon and ligament healing · D (Preclinical) | Prohibited — BPC-157 falls under WADA's S0 (non-approved substances) category |
| Cagrilintide | Long-acting amylin (and calcitonin) receptor agonist | Investigational | Weight loss (as monotherapy) · B (Supported) | Not prohibited by WADA |
| CJC-1295 | Long-acting GHRH analog | Research chemical | Raises GH and IGF-1 secretion · C (Preliminary) | Prohibited at all times under WADA category S2 (peptide hormones, growth factors, related substances and mimetics), which covers GHRH and its analogs |
| Dulaglutide | GLP-1 receptor agonist | FDA-approved | Glycemic control (type 2 diabetes) · A (Established) | Not prohibited by WADA |
| Epitalon | Synthetic tetrapeptide | Research chemical | Human aging biomarkers (melatonin rhythm, mortality in older cohorts) · C (Preliminary) | Not individually named on the WADA Prohibited List; as a non-approved peptide it may fall under the S0 (non-approved substances) category. Athletes should treat it as prohibited |
| Exenatide | GLP-1 receptor agonist | FDA-approved | Glycemic control (type 2 diabetes) · A (Established) | Not prohibited by WADA |
| GHK-Cu | Copper-binding tripeptide (glycyl-L-histidyl-L-lysine + Cu2+) | Status varies by jurisdiction | Skin appearance — wrinkles, firmness, texture (topical) · C (Preliminary) | — |
| GHRP-2 | Synthetic growth-hormone-releasing peptide (ghrelin receptor agonist) | Research chemical | Acute increase in growth hormone secretion · C (Preliminary) | Prohibited at all times under WADA category S2 (peptide hormones, growth factors, related substances, and mimetics), alongside other GH-releasing peptides |
| GHRP-6 | Synthetic growth-hormone-releasing hexapeptide (ghrelin receptor agonist) | Research chemical | Acute increase in growth hormone secretion · C (Preliminary) | Prohibited at all times under WADA category S2 (peptide hormones, growth factors, related substances, and mimetics) |
| Ipamorelin | Selective ghrelin/GH-secretagogue receptor agonist | Research chemical | Raises GH secretion · C (Preliminary) | Prohibited at all times under WADA category S2 (peptide hormones, growth factors, related substances and mimetics), which covers GH-releasing peptides and secretagogues |
| KPV | Anti-inflammatory tripeptide (C-terminal fragment of alpha-MSH) | Research chemical | Intestinal / colonic inflammation (colitis) · D (Preclinical) | — |
| Liraglutide | GLP-1 receptor agonist | FDA-approved | Glycemic control (type 2 diabetes) · A (Established) | Not prohibited by WADA |
| LL-37 | Human cathelicidin-derived antimicrobial / host-defense peptide (37 residues) | Research chemical | Antimicrobial / innate immune defense (endogenous role) · D (Preclinical) | — |
| MK-677 | Orally-active non-peptide ghrelin receptor agonist / growth hormone secretagogue | Investigational | Sustained increase in growth hormone and IGF-1 · B (Supported) | Prohibited at all times under WADA category S2 (peptide hormones, growth factors, related substances, and mimetics). Ibutamoren is explicitly named on the prohibited list |
| MOTS-c | Mitochondrial-derived peptide | Research chemical | Metabolic health / insulin sensitivity · D (Preclinical) | Not individually named on the WADA Prohibited List, but as a non-approved peptide it is likely captured by the S0 (non-approved substances) category; athletes should treat it as prohibited |
| Orforglipron | Oral non-peptide (small-molecule) GLP-1 receptor agonist | Investigational | Weight loss · B (Supported) | Not prohibited by WADA |
| Retatrutide | Triple GIP / GLP-1 / glucagon receptor agonist | Investigational | Weight loss · C (Preliminary) | Not specifically listed by WADA |
| Selank | Synthetic heptapeptide (Tuftsin analog) | Status varies by jurisdiction | Anxiety (generalized anxiety, adjustment/neurasthenia) · C (Preliminary) | Not individually named on the WADA Prohibited List. Its international regulatory status is ambiguous; athletes should verify before use |
| Semaglutide | GLP-1 receptor agonist | FDA-approved | Glycemic control (type 2 diabetes) · A (Established) | Not prohibited by WADA |
| Semax | Synthetic heptapeptide (ACTH(4-7) analog) | Status varies by jurisdiction | Cognitive / nootropic effects · C (Preliminary) | Not individually named on the WADA Prohibited List. Because it is approved in Russia its regulatory status is ambiguous internationally; athletes should verify before use |
| Sermorelin | GHRH (1-29) analog | Withdrawn | Stimulates GH release (diagnostic / pediatric GH deficiency) · B (Supported) | Prohibited at all times under WADA category S2 (peptide hormones, growth factors, related substances and mimetics), which covers GHRH and its analogs |
| TB-500 | Synthetic peptide fragment (related to Thymosin beta-4) | Research chemical | Tendon and ligament healing · D (Preclinical) | Prohibited at all times in sport. TB-500 and Thymosin beta-4 fall under WADA's S2 category (peptide hormones, growth factors, related substances, and mimetics) |
| Tesamorelin | Stabilized GHRH analog | FDA-approved | Visceral adipose tissue reduction (HIV lipodystrophy) · A (Established) | Prohibited at all times under WADA category S2 (peptide hormones, growth factors, related substances and mimetics), which covers GHRH and its analogs |
| Thymosin Beta-4 | Naturally occurring 43-amino-acid actin-binding peptide | Investigational | Corneal / ophthalmic wound healing (neurotrophic keratopathy, dry eye) · C (Preliminary) | Prohibited at all times in sport under WADA's S2 category (peptide hormones, growth factors, related substances, and mimetics) |
| Tirzepatide | Dual GIP / GLP-1 receptor agonist | FDA-approved | Weight loss · A (Established) | Not prohibited by WADA |
Citation: Synptide Compound Evidence Map, v1.0(synptide.com/datasets). Licensed CC BY 4.0 — free to reuse with attribution.